Massachusetts-based medical device startup DC Devices closed a $10.7 million funding round in support of its minimally invasive treatment for heart failure.
DC Devices "seeks to become the leading medical device company for the treatment of congestive heart failure," according to its page on the website of venture capital firm General Catalyst.
General Catalyst has invested previously in DC Devices and joined the latest funding round alongside Third Rock Ventures and new investor Lumira Capital, according to the Boston Business Journal.
DC Devices is developing a transcatheter diastolic heart failure treatment device, the InterAtrial Shunt, which aims to relieve excess pressure in the heart’s left atrium.
The company has already completed 1st-in-human studies and is amid enrollment for a European pilot trial, president & CEO George Fazio told the Journal.